Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease
The DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
Abstract
At present, the only iron (Fe) chelator in clinical use for the treatment of Fe overload disease is the tris-hydroxamate deferoxamine (DFO). However, DFO suffers from a number of disadvantages, including the need for subcutaneous infusion (12 to 24 hours a day, 5 or 6 times per week), its poor intestinal absorption, and high cost. Therefore, there is an urgent need for an efficient, economical, and orally effective Fe chelator. Pyridoxal isonicotinoyl hydrazone (PIH) is a tridentate Fe-chelating agent that shows high Fe chelation efficacy both in vitro in cell culture models and also in vivo in rats and mice. In addition, this chelator is relatively nontoxic, economical to synthesize, and orally effective, and it shows high selectivity and affinity for Fe. However, over the last 10 years the development of PIH and its analogs has largely been ignored because of justifiable interest in other ligands such as 1,2-dimethyl-3-hydroxypyrid-4-one (L1). Unfortunately, recent clinical trials have shown that significant complications occur with L1 therapy, and it is controversial whether this chelator is effective at reducing hepatic Fe levels in patients. Because of the current lack of a clinically useful Fe chelator to replace DFO, PIH and its analogs appear to be potential candidate compounds that warrant further investigation. In this review we will discuss the studies that have been performed to characterize these chelators at the chemical and biologic levels as effective agents for treating Fe overload. The evidence from the literature suggests that these ligands deserve further careful investigation as potential orally effective Fe chelators.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, pyridoxal isonicotinyl hydrazone (PIH) [1672,1715-1720] is a promising molecule (also proposed in anti-cancer therapy), although it is hydrolysed both in vivo and in vitro [1721].”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1716]
Citations
Cites
Critical Stability Constants: First Supplement
Martell, A. E., & Smith, R. M. (1982) · Springer eBooks · doi:10.1007/978-1-4615-6761-5 · Cited by 6,008
Partition coefficients and their uses
Leo, A., Hansch, C., & Elkins, D. (1971) · Chemical Reviews · doi:10.1021/cr60274a001 · Cited by 4,540
The pharmacological basis of therapeutics
Frank, A. L. (1981) · Environmental Research · doi:10.1016/0013-9351(81)90176-6 · Cited by 2,734
The Pharmacological Basis of Therapeutics
GOODMAN, L. S., & GILMAN, A. (1976) · Optometry and Vision Science · doi:10.1097/00006324-197604000-00018 · Cited by 1,260
Iron-Chelating Therapy and the Treatment of Thalassemia
Olivieri, N. F., & Brittenham, G. M. (1997) · Blood · doi:10.1182/blood.v89.3.739 · Cited by 1,089
Medical Treatment of Osteoarthritis
(1965) · The Lancet · doi:10.1016/s0140-6736(65)91263-8 · Cited by 554
Richardson, D., Tran, E., & Ponka, P. (1995) · Blood · doi:10.1182/blood.v86.11.4295.bloodjournal86114295 · Cited by 345
Self-citationIntestinal permeability: functional assessment and significance
Travis, S., & Menzies, I. (1992) · Clinical Science · doi:10.1042/cs0820471 · Cited by 333
Breuer, W., Epsztejn, S., & Cabantchik, Z. I. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.41.24209 · Cited by 326
Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major
Olivieri, N. F., Brittenham, G. M., Matsui, D., Berkovitch, M., Blendis, L. M., Cameron, R. G., McClelland, R. A., Liu, P. P., Templeton, D. M., & Koren, G. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321404 · Cited by 324
Research works printed but not linked: 6
- Olivieri, 1996, Randomized trial of deferiprone (L1) and deferoxamine (DFO) in thalassemia major [abstract], Blood, 88, 651a
- Olivieri, 1996, Long-term follow-up of body iron in patients with thalassemia major during therapy with the orally active iron chelator deferiprone (L1) [abstract], Blood, 88, 1229a
- World Health Organization, 1983, Community control of hereditary anaemias, Bull WHO, 61, 63
- Webb, 1988, Pyridoxal isonicotinoyl hydrazone (PIH): a promising new iron chelator, Birth Defects, 23, 63
- Sharma, 1989, Enteral pyridoxal isonicotinoyl hydrazone (PIH) is an effective chelator in experimental iron overload by promotion of biliary iron excretion [abstract], Hepatology, 10, 573
- Hider, 1982, UK Patent: GB-2118176
Cited by
Application of Metal Coordination Chemistry To Explore and Manipulate Cell Biology
Haas, K. L., & Franz, K. J. (2009) · Chemical Reviews · doi:10.1021/cr900134a · Cited by 984
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Kalinowski, D. S., & Richardson, D. R. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.2 · Cited by 721
“13A) (for reviews, see Richardson and Ponka, 1998; Buss et al., 2002b).”
BackgroundSelf-citationKell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
“ought to develop their own iron chelators that might exhibit the desirable properties listed above. One class of molecule includes isonicotinylhydrazones. Thus, pyridoxal isonicotinyl hydrazone (PIH) [1507; 1546, 1547, 1548, 1549, 1550, 1551] is a promising molecule (also proposed in anti-cancer therapy), although it…”
BackgroundLopes, G. K. B., Schulman, H. M., & Hermes-Lima, M. (1999) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(99)00117-8 · Cited by 476
Design of iron chelators with therapeutic application
Liu, Z. D., & Hider, R. C. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00050-4 · Cited by 287
Metadata
- Authors
- Richardson, D. R., & Ponka, P.
- Affiliations
- Royal Brisbane and Women's Hospital (AU)
- Corresponding author
- Richardson, D.R.
- ORCID
- Richardson, D.R.
- Venue
- Journal of Laboratory and Clinical Medicine
- Publisher
- Elsevier BV
- Published
- 1998-04
- Volume
- 131
- Issue
- 4
- Pages
- 306-315
- ISSN
- 0022-2143 (ISSN-L)
- OpenAlex
- W1995087031
- Cited by
- 126
- References
- 69
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 1 · 2023: 1 · 2022: 4 · 2021: 4 · 2020: 3 · 2019: 5 · 2018: 2 · 2017: 3 · 2015: 2 · 2014: 5 · 2013: 2 · 2012: 2
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of Laboratory and Clinical Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Heavy Metal Exposure and Toxicity
- Keywords
- pyridoxal isonicotinoyl hydrazone, iron chelators, oral iron chelation
- MeSH terms
- Animals, Iron Chelating Agents, Isoniazid, Pyridoxal, Iron Overload, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease. https://app.cochat.ai/papers/10.1016/s0022-2143(98)90180-9
- The paper
- Richardson, D. R., & Ponka, P. (1998). Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease. Journal of Laboratory and Clinical Medicine. https://doi.org/10.1016/s0022-2143(98)90180-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.